Acknowledgements
The authors thank p-value communications for editorial and medical writing assistance. p-value communications received funding from Mitsubishi Tanabe Pharma America, Inc., for their contributions.
Declaration of interest
Angela Genge is a consultant for Mitsubishi Tanabe Pharma America, AL-S Pharma, AveXis, Alexion, Alnylam Pharmaceuticals, Akcea Therapeutics, Biogen, AB Science, Roche, Novartis, Sanofi-Genzyme, UCB, and Brainstorm Cell Therapeutics. Benjamin Brooks is a consultant for Mitsubishi Tanabe Pharma America.